Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Insight Molecular Diagnostics Inc. before investing.

In this article, we go over a few key elements for understanding Insight Molecular Diagnostics Inc.’s stock price such as:

• Insight Molecular Diagnostics Inc.’s current stock price and volume
• Why Insight Molecular Diagnostics Inc.’s stock price changed recently
• Upgrades and downgrades for IMDX from analysts
• IMDX’s stock price momentum as measured by its relative strength

About Insight Molecular Diagnostics Inc. (IMDX)

Before we jump into Insight Molecular Diagnostics Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents. Insight Molecular Diagnostics Inc. was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.

Want to learn more about Insight Molecular Diagnostics Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Insight Molecular Diagnostics Inc..

Insight Molecular Diagnostics Inc.’s Stock Price as of Market Close

As of December 12, 2025, 4:00 PM, CST, Insight Molecular Diagnostics Inc.’s stock price was $5.215.

Insight Molecular Diagnostics Inc. is up 0.29% from its previous closing price of $5.200.

During the last market session, Insight Molecular Diagnostics Inc.’s stock traded between $5.070 and $5.250. Currently, there are approximately 32.03 million shares outstanding for Insight Molecular Diagnostics Inc..

Insight Molecular Diagnostics Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Insight Molecular Diagnostics Inc. Stock Price History

Insight Molecular Diagnostics Inc.’s (IMDX) price is currently down 15.07% so far this month.

During the month of December, Insight Molecular Diagnostics Inc.’s stock price has reached a high of $6.140 and a low of $4.910.

Over the last year, Insight Molecular Diagnostics Inc. has hit prices as high as $8.510 and as low as $1.922.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Insight Molecular Diagnostics Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 12, 2025, there was 1 analyst who downgraded Insight Molecular Diagnostics Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Insight Molecular Diagnostics Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Insight Molecular Diagnostics Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Insight Molecular Diagnostics Inc. (IMDX) by visiting AAII Stock Evaluator.

Relative Price Strength of Insight Molecular Diagnostics Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 12, 2025, Insight Molecular Diagnostics Inc. has a weighted four-quarter relative price strength of 28.71%, which translates to a Momentum Score of 94 and is considered to be Very Strong.

Want to learn more about how Insight Molecular Diagnostics Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Insight Molecular Diagnostics Inc. Stock Price: Bottom Line

As of December 12, 2025, Insight Molecular Diagnostics Inc.’s stock price is $5.215, which is up 0.29% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Insight Molecular Diagnostics Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Insight Molecular Diagnostics Inc. before investing.

In this article, we go over a few key elements for understanding Insight Molecular Diagnostics Inc.’s stock price such as:

• Insight Molecular Diagnostics Inc.’s current stock price and volume
• Why Insight Molecular Diagnostics Inc.’s stock price changed recently
• Upgrades and downgrades for IMDX from analysts
• IMDX’s stock price momentum as measured by its relative strength

About Insight Molecular Diagnostics Inc. (IMDX)

Before we jump into Insight Molecular Diagnostics Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents. Insight Molecular Diagnostics Inc. was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.

Want to learn more about Insight Molecular Diagnostics Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Insight Molecular Diagnostics Inc..

Insight Molecular Diagnostics Inc.’s Stock Price as of Market Close

As of December 12, 2025, 4:00 PM, CST, Insight Molecular Diagnostics Inc.’s stock price was $5.215.

Insight Molecular Diagnostics Inc. is up 0.29% from its previous closing price of $5.200.

During the last market session, Insight Molecular Diagnostics Inc.’s stock traded between $5.070 and $5.250. Currently, there are approximately 32.03 million shares outstanding for Insight Molecular Diagnostics Inc..

Insight Molecular Diagnostics Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Insight Molecular Diagnostics Inc. Stock Price History

Insight Molecular Diagnostics Inc.’s (IMDX) price is currently down 15.07% so far this month.

During the month of December, Insight Molecular Diagnostics Inc.’s stock price has reached a high of $6.140 and a low of $4.910.

Over the last year, Insight Molecular Diagnostics Inc. has hit prices as high as $8.510 and as low as $1.922.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Insight Molecular Diagnostics Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 12, 2025, there was 1 analyst who downgraded Insight Molecular Diagnostics Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Insight Molecular Diagnostics Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Insight Molecular Diagnostics Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Insight Molecular Diagnostics Inc. (IMDX) by visiting AAII Stock Evaluator.

Relative Price Strength of Insight Molecular Diagnostics Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 12, 2025, Insight Molecular Diagnostics Inc. has a weighted four-quarter relative price strength of 28.71%, which translates to a Momentum Score of 94 and is considered to be Very Strong.

Want to learn more about how Insight Molecular Diagnostics Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Insight Molecular Diagnostics Inc. Stock Price: Bottom Line

As of December 12, 2025, Insight Molecular Diagnostics Inc.’s stock price is $5.215, which is up 0.29% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Insight Molecular Diagnostics Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Insight Molecular Diagnostics Inc. before investing.

In this article, we go over a few key elements for understanding Insight Molecular Diagnostics Inc.’s stock price such as:

• Insight Molecular Diagnostics Inc.’s current stock price and volume
• Why Insight Molecular Diagnostics Inc.’s stock price changed recently
• Upgrades and downgrades for IMDX from analysts
• IMDX’s stock price momentum as measured by its relative strength

About Insight Molecular Diagnostics Inc. (IMDX)

Before we jump into Insight Molecular Diagnostics Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents. Insight Molecular Diagnostics Inc. was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.

Want to learn more about Insight Molecular Diagnostics Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Insight Molecular Diagnostics Inc..

Insight Molecular Diagnostics Inc.’s Stock Price as of Market Close

As of December 12, 2025, 4:00 PM, CST, Insight Molecular Diagnostics Inc.’s stock price was $5.215.

Insight Molecular Diagnostics Inc. is up 0.29% from its previous closing price of $5.200.

During the last market session, Insight Molecular Diagnostics Inc.’s stock traded between $5.070 and $5.250. Currently, there are approximately 32.03 million shares outstanding for Insight Molecular Diagnostics Inc..

Insight Molecular Diagnostics Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Insight Molecular Diagnostics Inc. Stock Price History

Insight Molecular Diagnostics Inc.’s (IMDX) price is currently down 15.07% so far this month.

During the month of December, Insight Molecular Diagnostics Inc.’s stock price has reached a high of $6.140 and a low of $4.910.

Over the last year, Insight Molecular Diagnostics Inc. has hit prices as high as $8.510 and as low as $1.922.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Insight Molecular Diagnostics Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 12, 2025, there was 1 analyst who downgraded Insight Molecular Diagnostics Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Insight Molecular Diagnostics Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Insight Molecular Diagnostics Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Insight Molecular Diagnostics Inc. (IMDX) by visiting AAII Stock Evaluator.

Relative Price Strength of Insight Molecular Diagnostics Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 12, 2025, Insight Molecular Diagnostics Inc. has a weighted four-quarter relative price strength of 28.71%, which translates to a Momentum Score of 94 and is considered to be Very Strong.

Want to learn more about how Insight Molecular Diagnostics Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Insight Molecular Diagnostics Inc. Stock Price: Bottom Line

As of December 12, 2025, Insight Molecular Diagnostics Inc.’s stock price is $5.215, which is up 0.29% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Insight Molecular Diagnostics Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Insight Molecular Diagnostics Inc. before investing.

In this article, we go over a few key elements for understanding Insight Molecular Diagnostics Inc.’s stock price such as:

• Insight Molecular Diagnostics Inc.’s current stock price and volume
• Why Insight Molecular Diagnostics Inc.’s stock price changed recently
• Upgrades and downgrades for IMDX from analysts
• IMDX’s stock price momentum as measured by its relative strength

About Insight Molecular Diagnostics Inc. (IMDX)

Before we jump into Insight Molecular Diagnostics Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents. Insight Molecular Diagnostics Inc. was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.

Want to learn more about Insight Molecular Diagnostics Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Insight Molecular Diagnostics Inc..

Insight Molecular Diagnostics Inc.’s Stock Price as of Market Close

As of December 12, 2025, 4:00 PM, CST, Insight Molecular Diagnostics Inc.’s stock price was $5.215.

Insight Molecular Diagnostics Inc. is up 0.29% from its previous closing price of $5.200.

During the last market session, Insight Molecular Diagnostics Inc.’s stock traded between $5.070 and $5.250. Currently, there are approximately 32.03 million shares outstanding for Insight Molecular Diagnostics Inc..

Insight Molecular Diagnostics Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Insight Molecular Diagnostics Inc. Stock Price History

Insight Molecular Diagnostics Inc.’s (IMDX) price is currently down 15.07% so far this month.

During the month of December, Insight Molecular Diagnostics Inc.’s stock price has reached a high of $6.140 and a low of $4.910.

Over the last year, Insight Molecular Diagnostics Inc. has hit prices as high as $8.510 and as low as $1.922.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Insight Molecular Diagnostics Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 12, 2025, there was 1 analyst who downgraded Insight Molecular Diagnostics Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Insight Molecular Diagnostics Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Insight Molecular Diagnostics Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Insight Molecular Diagnostics Inc. (IMDX) by visiting AAII Stock Evaluator.

Relative Price Strength of Insight Molecular Diagnostics Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 12, 2025, Insight Molecular Diagnostics Inc. has a weighted four-quarter relative price strength of 28.71%, which translates to a Momentum Score of 94 and is considered to be Very Strong.

Want to learn more about how Insight Molecular Diagnostics Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Insight Molecular Diagnostics Inc. Stock Price: Bottom Line

As of December 12, 2025, Insight Molecular Diagnostics Inc.’s stock price is $5.215, which is up 0.29% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Insight Molecular Diagnostics Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Insight Molecular Diagnostics Inc. before investing.

In this article, we go over a few key elements for understanding Insight Molecular Diagnostics Inc.’s stock price such as:

• Insight Molecular Diagnostics Inc.’s current stock price and volume
• Why Insight Molecular Diagnostics Inc.’s stock price changed recently
• Upgrades and downgrades for IMDX from analysts
• IMDX’s stock price momentum as measured by its relative strength

About Insight Molecular Diagnostics Inc. (IMDX)

Before we jump into Insight Molecular Diagnostics Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents. Insight Molecular Diagnostics Inc. was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.

Want to learn more about Insight Molecular Diagnostics Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Insight Molecular Diagnostics Inc..

Insight Molecular Diagnostics Inc.’s Stock Price as of Market Close

As of December 12, 2025, 4:00 PM, CST, Insight Molecular Diagnostics Inc.’s stock price was $5.215.

Insight Molecular Diagnostics Inc. is up 0.29% from its previous closing price of $5.200.

During the last market session, Insight Molecular Diagnostics Inc.’s stock traded between $5.070 and $5.250. Currently, there are approximately 32.03 million shares outstanding for Insight Molecular Diagnostics Inc..

Insight Molecular Diagnostics Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Insight Molecular Diagnostics Inc. Stock Price History

Insight Molecular Diagnostics Inc.’s (IMDX) price is currently down 15.07% so far this month.

During the month of December, Insight Molecular Diagnostics Inc.’s stock price has reached a high of $6.140 and a low of $4.910.

Over the last year, Insight Molecular Diagnostics Inc. has hit prices as high as $8.510 and as low as $1.922.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Insight Molecular Diagnostics Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 12, 2025, there was 1 analyst who downgraded Insight Molecular Diagnostics Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Insight Molecular Diagnostics Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Insight Molecular Diagnostics Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Insight Molecular Diagnostics Inc. (IMDX) by visiting AAII Stock Evaluator.

Relative Price Strength of Insight Molecular Diagnostics Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 12, 2025, Insight Molecular Diagnostics Inc. has a weighted four-quarter relative price strength of 28.71%, which translates to a Momentum Score of 94 and is considered to be Very Strong.

Want to learn more about how Insight Molecular Diagnostics Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Insight Molecular Diagnostics Inc. Stock Price: Bottom Line

As of December 12, 2025, Insight Molecular Diagnostics Inc.’s stock price is $5.215, which is up 0.29% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Insight Molecular Diagnostics Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Insight Molecular Diagnostics Inc. before investing.

In this article, we go over a few key elements for understanding Insight Molecular Diagnostics Inc.’s stock price such as:

• Insight Molecular Diagnostics Inc.’s current stock price and volume
• Why Insight Molecular Diagnostics Inc.’s stock price changed recently
• Upgrades and downgrades for IMDX from analysts
• IMDX’s stock price momentum as measured by its relative strength

About Insight Molecular Diagnostics Inc. (IMDX)

Before we jump into Insight Molecular Diagnostics Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents. Insight Molecular Diagnostics Inc. was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.

Want to learn more about Insight Molecular Diagnostics Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Insight Molecular Diagnostics Inc..

Insight Molecular Diagnostics Inc.’s Stock Price as of Market Close

As of December 12, 2025, 4:00 PM, CST, Insight Molecular Diagnostics Inc.’s stock price was $5.215.

Insight Molecular Diagnostics Inc. is up 0.29% from its previous closing price of $5.200.

During the last market session, Insight Molecular Diagnostics Inc.’s stock traded between $5.070 and $5.250. Currently, there are approximately 32.03 million shares outstanding for Insight Molecular Diagnostics Inc..

Insight Molecular Diagnostics Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Insight Molecular Diagnostics Inc. Stock Price History

Insight Molecular Diagnostics Inc.’s (IMDX) price is currently down 15.07% so far this month.

During the month of December, Insight Molecular Diagnostics Inc.’s stock price has reached a high of $6.140 and a low of $4.910.

Over the last year, Insight Molecular Diagnostics Inc. has hit prices as high as $8.510 and as low as $1.922.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Insight Molecular Diagnostics Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 12, 2025, there was 1 analyst who downgraded Insight Molecular Diagnostics Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Insight Molecular Diagnostics Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Insight Molecular Diagnostics Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Insight Molecular Diagnostics Inc. (IMDX) by visiting AAII Stock Evaluator.

Relative Price Strength of Insight Molecular Diagnostics Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 12, 2025, Insight Molecular Diagnostics Inc. has a weighted four-quarter relative price strength of 28.71%, which translates to a Momentum Score of 94 and is considered to be Very Strong.

Want to learn more about how Insight Molecular Diagnostics Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Insight Molecular Diagnostics Inc. Stock Price: Bottom Line

As of December 12, 2025, Insight Molecular Diagnostics Inc.’s stock price is $5.215, which is up 0.29% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Insight Molecular Diagnostics Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Insight Molecular Diagnostics Inc. before investing.

In this article, we go over a few key elements for understanding Insight Molecular Diagnostics Inc.’s stock price such as:

• Insight Molecular Diagnostics Inc.’s current stock price and volume
• Why Insight Molecular Diagnostics Inc.’s stock price changed recently
• Upgrades and downgrades for IMDX from analysts
• IMDX’s stock price momentum as measured by its relative strength

About Insight Molecular Diagnostics Inc. (IMDX)

Before we jump into Insight Molecular Diagnostics Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents. Insight Molecular Diagnostics Inc. was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.

Want to learn more about Insight Molecular Diagnostics Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Insight Molecular Diagnostics Inc..

Insight Molecular Diagnostics Inc.’s Stock Price as of Market Close

As of December 12, 2025, 4:00 PM, CST, Insight Molecular Diagnostics Inc.’s stock price was $5.215.

Insight Molecular Diagnostics Inc. is up 0.29% from its previous closing price of $5.200.

During the last market session, Insight Molecular Diagnostics Inc.’s stock traded between $5.070 and $5.250. Currently, there are approximately 32.03 million shares outstanding for Insight Molecular Diagnostics Inc..

Insight Molecular Diagnostics Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Insight Molecular Diagnostics Inc. Stock Price History

Insight Molecular Diagnostics Inc.’s (IMDX) price is currently down 15.07% so far this month.

During the month of December, Insight Molecular Diagnostics Inc.’s stock price has reached a high of $6.140 and a low of $4.910.

Over the last year, Insight Molecular Diagnostics Inc. has hit prices as high as $8.510 and as low as $1.922.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Insight Molecular Diagnostics Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 12, 2025, there was 1 analyst who downgraded Insight Molecular Diagnostics Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Insight Molecular Diagnostics Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Insight Molecular Diagnostics Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Insight Molecular Diagnostics Inc. (IMDX) by visiting AAII Stock Evaluator.

Relative Price Strength of Insight Molecular Diagnostics Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 12, 2025, Insight Molecular Diagnostics Inc. has a weighted four-quarter relative price strength of 28.71%, which translates to a Momentum Score of 94 and is considered to be Very Strong.

Want to learn more about how Insight Molecular Diagnostics Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Insight Molecular Diagnostics Inc. Stock Price: Bottom Line

As of December 12, 2025, Insight Molecular Diagnostics Inc.’s stock price is $5.215, which is up 0.29% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Insight Molecular Diagnostics Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Insight Molecular Diagnostics Inc. before investing.

In this article, we go over a few key elements for understanding Insight Molecular Diagnostics Inc.’s stock price such as:

• Insight Molecular Diagnostics Inc.’s current stock price and volume
• Why Insight Molecular Diagnostics Inc.’s stock price changed recently
• Upgrades and downgrades for IMDX from analysts
• IMDX’s stock price momentum as measured by its relative strength

About Insight Molecular Diagnostics Inc. (IMDX)

Before we jump into Insight Molecular Diagnostics Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents. Insight Molecular Diagnostics Inc. was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.

Want to learn more about Insight Molecular Diagnostics Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Insight Molecular Diagnostics Inc..

Insight Molecular Diagnostics Inc.’s Stock Price as of Market Close

As of December 12, 2025, 4:00 PM, CST, Insight Molecular Diagnostics Inc.’s stock price was $5.215.

Insight Molecular Diagnostics Inc. is up 0.29% from its previous closing price of $5.200.

During the last market session, Insight Molecular Diagnostics Inc.’s stock traded between $5.070 and $5.250. Currently, there are approximately 32.03 million shares outstanding for Insight Molecular Diagnostics Inc..

Insight Molecular Diagnostics Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Insight Molecular Diagnostics Inc. Stock Price History

Insight Molecular Diagnostics Inc.’s (IMDX) price is currently down 15.07% so far this month.

During the month of December, Insight Molecular Diagnostics Inc.’s stock price has reached a high of $6.140 and a low of $4.910.

Over the last year, Insight Molecular Diagnostics Inc. has hit prices as high as $8.510 and as low as $1.922.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Insight Molecular Diagnostics Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 12, 2025, there was 1 analyst who downgraded Insight Molecular Diagnostics Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Insight Molecular Diagnostics Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Insight Molecular Diagnostics Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Insight Molecular Diagnostics Inc. (IMDX) by visiting AAII Stock Evaluator.

Relative Price Strength of Insight Molecular Diagnostics Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 12, 2025, Insight Molecular Diagnostics Inc. has a weighted four-quarter relative price strength of 28.71%, which translates to a Momentum Score of 94 and is considered to be Very Strong.

Want to learn more about how Insight Molecular Diagnostics Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Insight Molecular Diagnostics Inc. Stock Price: Bottom Line

As of December 12, 2025, Insight Molecular Diagnostics Inc.’s stock price is $5.215, which is up 0.29% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Insight Molecular Diagnostics Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.